Arrivo BioVentures, which emerged from stealth mode less than two years ago with $49 million in funding and four drug candidates, has raised another $45 million and plans to advance its treatment focused on major depression disorder or MDD.
RESEARCH TRIANGLE PARK - Five years after launching with a team headlined by local life sciences "rainmaker" Steve Butts and $49 million in capital, Arrivo
Five years after launching with a team headlined by local life sciences “rainmaker” Steve Butts and $49 million in capital, Morrisville-based Arrivo BioVentures is emerging from stealth mode with four drugs in its pipeline.